Stroke:选择性5-羟色胺再摄取抑制剂与脑出血的风险和结局

2020-03-04 xing.T MedSci原创

在这大型的多民族队列中,ICH前SSRI使用与ICH风险增加无关,但ICH后SSRI使用与ICH后3个月不良的神经系统结局有关。

选择性5-羟色胺再摄取抑制剂(SSRI)与出血并发症有关,而对卒中后结局的报道相互矛盾。近日,心血管疾病领域权威杂志Stroke上发表了一篇研究文章,研究人员试图评估脑出血(ICH)前使用SSRI是否会增加ICH风险,以及ICH后使用SSRI后是否可改善ICH结局。

研究人员通过对ERICH研究的事后分析(脑出血的种族/民族差异),SSRI的使用情况被分为不使用、仅在ICH之前使用、在ICH之前和之后都使用(称为“连续”使用)以及仅在ICH之后使用(称为“新”使用者)。研究人员使用多变量建模,在病例对照组中寻找ICH前SSRI使用与ICH风险之间的关联,并在ICH病例组中分析ICH后SSRI使用与3个月结局之间的关联。探索性分析试图评估模型中种族/民族的影响。

最后的研究队列共包含2287例ICH病例和2895例对照者。ICH前使用SSRI与ICH风险无关(比值比为0.824[95%CI为0.632-1.074]),抗凝药或抗血小板药物的使用也与增加的ICH风险无关。在多变量分析中,ICH后SSRI使用与ICH后3个月不良的改良Rankin量表评分相关(比值比为1.673 [95%CI为1.162-2.408;P=0.006])。其他倾向得分分析得到相似的趋势,但未达到统计学显著性(P=0.107)。如果按种族/民族进行分层,多变量建模表明在西班牙裔患者ICH前使用SSRI可以降低ICH风险(比值比为0.513 [95%CI为0.301-0.875]; P=0.014),而非西班牙裔白人或黑人除外。在任何种族/民族群体中,ICH后使用SSRI与3个月结局之间均无关联。

在这大型的多民族队列中,ICH前SSRI使用与ICH风险增加无关,但ICH后SSRI使用与ICH后3个月不良的神经系统结局有关。

原始出处:

Li Liu.et al.Selective Serotonin Reuptake Inhibitors and Intracerebral Hemorrhage Risk and Outcome.stroke.2020.https://www.ahajournals.org/doi/10.1161/STROKEAHA.119.028406

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1779243, encodeId=88f81e7924324, content=<a href='/topic/show?id=c63c140461' target=_blank style='color:#2F92EE;'>#5-羟色胺再摄取#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1404, encryptionId=c63c140461, topicName=5-羟色胺再摄取)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Nov 26 19:47:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922953, encodeId=04ef192295341, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Oct 15 17:47:00 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778867, encodeId=212e1e78867aa, content=<a href='/topic/show?id=c63c140461' target=_blank style='color:#2F92EE;'>#5-羟色胺再摄取#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1404, encryptionId=c63c140461, topicName=5-羟色胺再摄取)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Mar 12 18:47:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852290, encodeId=79d1185229045, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu May 07 23:47:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420602, encodeId=f4f614206024b, content=<a href='/topic/show?id=be7994e8150' target=_blank style='color:#2F92EE;'>#选择性5-羟色胺再摄取抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94781, encryptionId=be7994e8150, topicName=选择性5-羟色胺再摄取抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91ed3584304, createdName=liuyiping, createdTime=Fri Mar 06 09:47:00 CST 2020, time=2020-03-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1779243, encodeId=88f81e7924324, content=<a href='/topic/show?id=c63c140461' target=_blank style='color:#2F92EE;'>#5-羟色胺再摄取#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1404, encryptionId=c63c140461, topicName=5-羟色胺再摄取)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Nov 26 19:47:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922953, encodeId=04ef192295341, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Oct 15 17:47:00 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778867, encodeId=212e1e78867aa, content=<a href='/topic/show?id=c63c140461' target=_blank style='color:#2F92EE;'>#5-羟色胺再摄取#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1404, encryptionId=c63c140461, topicName=5-羟色胺再摄取)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Mar 12 18:47:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852290, encodeId=79d1185229045, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu May 07 23:47:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420602, encodeId=f4f614206024b, content=<a href='/topic/show?id=be7994e8150' target=_blank style='color:#2F92EE;'>#选择性5-羟色胺再摄取抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94781, encryptionId=be7994e8150, topicName=选择性5-羟色胺再摄取抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91ed3584304, createdName=liuyiping, createdTime=Fri Mar 06 09:47:00 CST 2020, time=2020-03-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1779243, encodeId=88f81e7924324, content=<a href='/topic/show?id=c63c140461' target=_blank style='color:#2F92EE;'>#5-羟色胺再摄取#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1404, encryptionId=c63c140461, topicName=5-羟色胺再摄取)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Nov 26 19:47:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922953, encodeId=04ef192295341, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Oct 15 17:47:00 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778867, encodeId=212e1e78867aa, content=<a href='/topic/show?id=c63c140461' target=_blank style='color:#2F92EE;'>#5-羟色胺再摄取#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1404, encryptionId=c63c140461, topicName=5-羟色胺再摄取)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Mar 12 18:47:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852290, encodeId=79d1185229045, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu May 07 23:47:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420602, encodeId=f4f614206024b, content=<a href='/topic/show?id=be7994e8150' target=_blank style='color:#2F92EE;'>#选择性5-羟色胺再摄取抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94781, encryptionId=be7994e8150, topicName=选择性5-羟色胺再摄取抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91ed3584304, createdName=liuyiping, createdTime=Fri Mar 06 09:47:00 CST 2020, time=2020-03-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1779243, encodeId=88f81e7924324, content=<a href='/topic/show?id=c63c140461' target=_blank style='color:#2F92EE;'>#5-羟色胺再摄取#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1404, encryptionId=c63c140461, topicName=5-羟色胺再摄取)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Nov 26 19:47:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922953, encodeId=04ef192295341, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Oct 15 17:47:00 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778867, encodeId=212e1e78867aa, content=<a href='/topic/show?id=c63c140461' target=_blank style='color:#2F92EE;'>#5-羟色胺再摄取#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1404, encryptionId=c63c140461, topicName=5-羟色胺再摄取)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Mar 12 18:47:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852290, encodeId=79d1185229045, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu May 07 23:47:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420602, encodeId=f4f614206024b, content=<a href='/topic/show?id=be7994e8150' target=_blank style='color:#2F92EE;'>#选择性5-羟色胺再摄取抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94781, encryptionId=be7994e8150, topicName=选择性5-羟色胺再摄取抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91ed3584304, createdName=liuyiping, createdTime=Fri Mar 06 09:47:00 CST 2020, time=2020-03-06, status=1, ipAttribution=)]
    2020-05-07 jklm09
  5. [GetPortalCommentsPageByObjectIdResponse(id=1779243, encodeId=88f81e7924324, content=<a href='/topic/show?id=c63c140461' target=_blank style='color:#2F92EE;'>#5-羟色胺再摄取#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1404, encryptionId=c63c140461, topicName=5-羟色胺再摄取)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Nov 26 19:47:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922953, encodeId=04ef192295341, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Thu Oct 15 17:47:00 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778867, encodeId=212e1e78867aa, content=<a href='/topic/show?id=c63c140461' target=_blank style='color:#2F92EE;'>#5-羟色胺再摄取#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1404, encryptionId=c63c140461, topicName=5-羟色胺再摄取)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Mar 12 18:47:00 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852290, encodeId=79d1185229045, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu May 07 23:47:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420602, encodeId=f4f614206024b, content=<a href='/topic/show?id=be7994e8150' target=_blank style='color:#2F92EE;'>#选择性5-羟色胺再摄取抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94781, encryptionId=be7994e8150, topicName=选择性5-羟色胺再摄取抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91ed3584304, createdName=liuyiping, createdTime=Fri Mar 06 09:47:00 CST 2020, time=2020-03-06, status=1, ipAttribution=)]

相关资讯

JAMA:应激障碍、继自身免疫性疾病与选择性5-羟色胺再摄取抑制剂治疗

研究认为,应激障碍导致后继自身免疫性疾病风险增加,坚持选择性5-羟色胺再摄取抑制剂可降低患者后继免疫疾病风险

BMJ:选择性5-羟色胺再摄取抑制剂联合他莫昔芬并不增加患者死亡的发生风险

本研究旨在对比女性中与单独使用他莫昔芬和选择性5-羟色胺再摄取抑制剂(SSRIs)——细胞色素P450 2D6酶(CYP2D6)的强效抑制剂,同时使用他莫昔芬和SSRIs治疗时死亡率的差异。 采用基于人口的队列研究,纳入五个美国的数据库,涵盖1995年至2013年注册个人和公共健康保险计划的人群。 两个队列中女性开始服用他莫昔芬。队列1中,在服用他莫昔芬时开始服用SSRI。队列2中,在

Pediatrics :SSRI对青少年身体成分的影响

肥胖和重度抑郁症(MDD)具有相互关联的作用,下丘脑-垂体-肾上腺素的失调,其他内分泌异常,自主神经系统功能障碍,亚临床炎症和生活方式等因素也参与其中。此外,大多数精神科药物也引起体重增加。然而,研究肥胖与MDD之间关系的纵向研究未能解释其精神药理学,也没有检查体重指数(BMI)以外的肥胖症(即身体脂肪和内脏脂肪)。